A previous study has demonstrated improved CR rates with VEN and azacitidine compared to azacitidine alone in AML patients with poor-risk cytogenetics and TP53 mutations, but the value of adding venetoclax has not been confirmed in other studies [32,33]. The gene discussed is TP53; the disease is acute myeloid leukemia.